- Home
- GXAI vs HSCS Comparison
GXAI vs HSCS Comparison
Compare GXAI & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- HSCS
- Stock Information
- Founded
- GXAI 2021
- HSCS 2007
- Country
- GXAI United States
- HSCS United States
- Employees
- GXAI N/A
- HSCS N/A
- Industry
- GXAI
- HSCS Medical Specialities
- Sector
- GXAI
- HSCS Health Care
- Exchange
- GXAI Nasdaq
- HSCS Nasdaq
- Market Cap
- GXAI 12.0M
- HSCS 9.9M
- IPO Year
- GXAI 2023
- HSCS 2022
- Fundamental
- Price
- GXAI $1.84
- HSCS $3.64
- Analyst Decision
- GXAI
- HSCS Strong Buy
- Analyst Count
- GXAI 0
- HSCS 2
- Target Price
- GXAI N/A
- HSCS $10.50
- AVG Volume (30 Days)
- GXAI 353.1K
- HSCS 93.2K
- Earning Date
- GXAI 11-13-2025
- HSCS 09-11-2025
- Dividend Yield
- GXAI N/A
- HSCS N/A
- EPS Growth
- GXAI N/A
- HSCS N/A
- EPS
- GXAI N/A
- HSCS N/A
- Revenue
- GXAI $198,711.00
- HSCS $6,250.00
- Revenue This Year
- GXAI N/A
- HSCS $13,968.97
- Revenue Next Year
- GXAI N/A
- HSCS $166.67
- P/E Ratio
- GXAI N/A
- HSCS N/A
- Revenue Growth
- GXAI 72158.55
- HSCS N/A
- 52 Week Low
- GXAI $1.00
- HSCS $2.52
- 52 Week High
- GXAI $7.50
- HSCS $6.47
- Technical
- Relative Strength Index (RSI)
- GXAI 55.95
- HSCS 53.87
- Support Level
- GXAI $1.55
- HSCS $3.29
- Resistance Level
- GXAI $2.00
- HSCS $3.80
- Average True Range (ATR)
- GXAI 0.15
- HSCS 0.18
- MACD
- GXAI 0.00
- HSCS 0.02
- Stochastic Oscillator
- GXAI 64.42
- HSCS 69.61
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.